EcoDrugPlus

Protein Tyrosine Kinase 2 Beta

Ensembl ID : ENSOCUG00000007668
Gene Symbol: PTK2B
2 Cross references
269 Possible Orthologues:

Protein Tyrosine Phosphatase Non-Receptor Type 11

Ensembl ID : ENSOCUG00000004533
Gene Symbol: PTPN11
2 Cross references
251 Possible Orthologues:

Protein Tyrosine Phosphatase Receptor Type B

Ensembl ID : ENSOCUG00000012045
Gene Symbol: PTPRB
2 Cross references
264 Possible Orthologues:

Purine Nucleoside Phosphorylase

Ensembl ID : ENSOCUG00000005027
Gene Symbol: PNP
2 Cross references
429 Possible Orthologues:

Purinergic Receptor P2x 3

Ensembl ID : ENSOCUG00000003082
Gene Symbol: P2RX3
2 Cross references
270 Possible Orthologues:

Purinergic Receptor P2x 7

Ensembl ID : ENSOCUG00000008823
Gene Symbol: P2RX7
3 Cross references
187 Possible Orthologues:

Purinergic Receptor P2y1

Ensembl ID : ENSOCUG00000010828
Gene Symbol: P2RY1
3 Cross references
190 Possible Orthologues:

Pyrimidinergic Receptor P2y4

Ensembl ID : ENSOCUG00000017070
Gene Symbol: P2RY4
2 Cross references
165 Possible Orthologues:

Pyrimidinergic Receptor P2y6

Ensembl ID : ENSOCUG00000017568
Gene Symbol: P2RY6
2 Cross references
182 Possible Orthologues:

Receptor Interacting Serine/threonine Kinase 1

Ensembl ID : ENSOCUG00000011791
Gene Symbol: RIPK1
3 Cross references
197 Possible Orthologues:

Renin

Ensembl ID : ENSOCUG00000023929
Gene Symbol: REN
2 Cross references
218 Possible Orthologues:

Ret Proto-Oncogene

Ensembl ID : ENSOCUG00000011141
Gene Symbol: RET
2 Cross references
204 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).